HOOKIPA Pharma Inc HOOK.OQ HOOK.O is expected to show a fall in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
The New York City-based company is expected to report a 9.0% decrease in revenue to $6.25 million from $6.87 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for HOOKIPA Pharma Inc is for a loss of $1.28 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for HOOKIPA Pharma Inc is $50.00, above its last closing price of $3.81.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.29 | -1.25 | -1.52 | Missed | -21.4 |
Mar. 31 2024 | -1.07 | -1.02 | 1.10 | Beat | 207.3 |
Jan. 1 0001 | -1.96 | -1.93 | -2.20 | Missed | -14 |
Sep. 30 2023 | -2.31 | -2.10 | -1.70 | Beat | 19 |
Jun. 30 2023 | -1.86 | -2.09 | -2.20 | Missed | -5.3 |
Mar. 31 2023 | -2.23 | -2.26 | -2.70 | Missed | -19.5 |
Dec. 31 2022 | -1.78 | -2.15 | -1.70 | Beat | 20.9 |
Jan. 1 0001 | -2.87 | -2.82 | -2.50 | Beat | 11.2 |
This summary was machine generated November 6 at 14:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。